These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28459045)

  • 41. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early termination of pivotal trials in Alzheimer's disease-Preserving optimal value for participants and science.
    Gietl AF; Frisoni GB
    Alzheimers Dement; 2022 Oct; 18(10):1980-1987. PubMed ID: 35220681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years.
    Walter S; Langford OG; Clanton TB; Jimenez-Maggiora GA; Raman R; Rafii MS; Shaffer EJ; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):234-241. PubMed ID: 32920625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Salazar J; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2017 May; 13(5):561-571. PubMed ID: 27931796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan.
    Siemers E; Hitchcock J; Sundell K; Dean R; Jerecic J; Cline E; Iverson K; Moore J; Edgar C; Manber R; Fuin N; Poppe T; Barton R
    J Prev Alzheimers Dis; 2023; 10(1):19-24. PubMed ID: 36641606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
    Gauthier S; Leuzy A; Racine E; Rosa-Neto P
    Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology.
    Jimenez-Maggiora GA; Bruschi S; Raman R; Langford O; Donohue M; Rafii MS; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):226-233. PubMed ID: 32920624
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network.
    Pavlik VN; Burnham SC; Kass JS; Helmer C; Palmqvist S; Vassilaki M; Dartigues JF; Hansson O; Masters CL; Pérès K; Petersen RC; Stomrud E; Butler L; Coloma PM; Teitsma XM; Doody R; Sano M;
    J Alzheimers Dis; 2022; 85(1):31-45. PubMed ID: 34776434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.
    Arnerić SP; Batrla-Utermann R; Beckett L; Bittner T; Blennow K; Carter L; Dean R; Engelborghs S; Genius J; Gordon MF; Hitchcock J; Kaplow J; Luthman J; Meibach R; Raunig D; Romero K; Samtani MN; Savage M; Shaw L; Stephenson D; Umek RM; Vanderstichele H; Willis B; Yule S
    J Alzheimers Dis; 2017; 55(1):19-35. PubMed ID: 27662307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mismatched double-stranded RNA: polyI:polyC12U.
    Adis Editorial
    Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recruitment and Screening Methods in Alzheimer's Disease Research: The FIT-AD Trial.
    Greimel S; Wyman JF; Zhang L; Yu F
    J Gerontol A Biol Sci Med Sci; 2022 Mar; 77(3):547-553. PubMed ID: 33780529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The China tuberculosis clinical trials consortium network: a model for international TB clinical trials capacity building.
    Liu YH; Chen S; Gao JT; Zhang Y; Booher K; Ding XF; Shu W; Du J; Bao J; Hafner R; Hamilton CD; Li L
    Infect Dis Poverty; 2020 May; 9(1):52. PubMed ID: 32414419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer's disease: study protocol of a randomized controlled trial (The FIT-AD trial).
    Yu F; Bronas UG; Konety S; Nelson NW; Dysken M; Jack C; Wyman JF; Vock D; Smith G
    Trials; 2014 Oct; 15():394. PubMed ID: 25304364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Challenges to and Facilitators of Recruitment to an Alzheimer's Disease Clinical Trial: A Qualitative Interview Study.
    Clement C; Selman LE; Kehoe PG; Howden B; Lane JA; Horwood J
    J Alzheimers Dis; 2019; 69(4):1067-1075. PubMed ID: 31156168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial.
    Reiman EM; Pruzin JJ; Rios-Romenets S; Brown C; Giraldo M; Acosta-Baena N; Tobon C; Hu N; Chen Y; Ghisays V; Enos J; Goradia DD; Lee W; Luo J; Malek-Ahmadi M; Protas H; Thomas RG; Chen K; Su Y; Boker C; Mastroeni D; Alvarez S; Quiroz YT; Langbaum JB; Sink KM; Lopera F; Tariot PN;
    Alzheimers Dement; 2023 May; 19(5):1938-1946. PubMed ID: 36373344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cohort Effects in Alzheimer's Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer's Disease Cooperative Study.
    Birnbaum AI; Grill JD; Gillen DL
    J Prev Alzheimers Dis; 2023; 10(3):471-477. PubMed ID: 37357287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Attitudes toward clinical trials across the Alzheimer's disease spectrum.
    Nuño MM; Gillen DL; Dosanjh KK; Brook J; Elashoff D; Ringman JM; Grill JD
    Alzheimers Res Ther; 2017 Oct; 9(1):81. PubMed ID: 28978335
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population.
    Uspenskaya-Cadoz O; Alamuri C; Wang L; Yang M; Khinda S; Nigmatullina Y; Cao T; Kayal N; O'Keefe M; Rubel C
    J Prev Alzheimers Dis; 2019; 6(3):185-191. PubMed ID: 31062833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.